BioSpace News Archive

The NEJM Evidence has published interim data from the first part of Phase I/II CYPIDES trial evaluating the safety and efficacy of ODM-208, an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Kuros Biosciences, a leader in next generation bone graft technologies, announced results from two prospective, randomized clinical studies - the STRUCTURE and MAXA trials.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company announced that Janet Rehnquist has been elected to the Company’s Board of Directors where she will chair the compliance and the nominating committees.

First Wave BioPharma, Inc.,, a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases such as ulcerative colitis and related conditions to an undisclosed biopharmaceutical company.

Seegene Inc. announced that it has achieved an ISO45001 certification on December 27.

Xeris Biopharma Holdings, Inc. announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time.

Zevra Therapeutics, Inc. a rare disease therapeutics company, announced it resubmitted its New Drug Application for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C to the U.S. Food and Drug Administration on December 22, 2023.

Matinas BioPharma Holdings, Inc. announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

Cytokinetics, Incorporated announced positive topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.

BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart, announced that Raymond W. Cohen has been appointed chairman of its board of directors.